Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the excessive deposition of extracellular matrix (ECM), which is thought to contribute to this tumor’s malignant behavior. However, the detailed mechanism and the contribution of excessive deposition of ECM in PDAC progression remain unclear. A better understanding of the mechanism involved in this process is essential for the design of new effective therapies. In this study, we demonstrated that pancreatic cancer cells exhibited increased proliferation and decreased apoptosis in response to type I collagen. In addition, PDAC cells exposed to type I collagen lost the expression of E-cadherin and increased expression of mesenchymal markers, including N-cadherin and vimentin. This epithelial- mesenchymal transition (EMT) was correlated with enhanced cell migration and invasiveness. Knockdown of β1-integrin abolished the effects induced by type I collagen, and further investigation revealed that type I collagen activates β1-integrin (marked by phosphorylation of β1 integrin downstream effectors, focal adhesion kinase [FAK], AKT, and ERK) accompanied by markedly up-regulation of Gli-1, a component of the Hedgehog (HH) pathway. Knockdown of Gli-1 reversed the effects of type I collagen on PDAC invasion and EMT. These results suggest that there is cross-talk between the β1-integrin signaling pathway and the HH pathway in pancreatic cancer and that activation of the HH pathway plays a key role in the type I collagen-induced effects on pancreatic cancer.
Keywords: Desmoplastic reaction, epithelial–mesenchymal transition, extracellular matrix, hedgehog pathway, β1-integrin, pancreatic cancer.
Current Cancer Drug Targets
Title:The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer
Volume: 14 Issue: 5
Author(s): Wanxing Duan, Jiguang Ma, Qingyong Ma, Qinhong Xu, Jianjun Lei, Liang Han, Xuqi Li, Zheng Wang, Zheng Wu, Shifang Lv, Zhenhua Ma, Mouzhu Liu, Fengfei Wang and Erxi Wu
Affiliation:
Keywords: Desmoplastic reaction, epithelial–mesenchymal transition, extracellular matrix, hedgehog pathway, β1-integrin, pancreatic cancer.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the excessive deposition of extracellular matrix (ECM), which is thought to contribute to this tumor’s malignant behavior. However, the detailed mechanism and the contribution of excessive deposition of ECM in PDAC progression remain unclear. A better understanding of the mechanism involved in this process is essential for the design of new effective therapies. In this study, we demonstrated that pancreatic cancer cells exhibited increased proliferation and decreased apoptosis in response to type I collagen. In addition, PDAC cells exposed to type I collagen lost the expression of E-cadherin and increased expression of mesenchymal markers, including N-cadherin and vimentin. This epithelial- mesenchymal transition (EMT) was correlated with enhanced cell migration and invasiveness. Knockdown of β1-integrin abolished the effects induced by type I collagen, and further investigation revealed that type I collagen activates β1-integrin (marked by phosphorylation of β1 integrin downstream effectors, focal adhesion kinase [FAK], AKT, and ERK) accompanied by markedly up-regulation of Gli-1, a component of the Hedgehog (HH) pathway. Knockdown of Gli-1 reversed the effects of type I collagen on PDAC invasion and EMT. These results suggest that there is cross-talk between the β1-integrin signaling pathway and the HH pathway in pancreatic cancer and that activation of the HH pathway plays a key role in the type I collagen-induced effects on pancreatic cancer.
Export Options
About this article
Cite this article as:
Duan Wanxing, Ma Jiguang, Ma Qingyong, Xu Qinhong, Lei Jianjun, Han Liang, Li Xuqi, Wang Zheng, Wu Zheng, Lv Shifang, Ma Zhenhua, Liu Mouzhu, Wang Fengfei and Wu Erxi, The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer, Current Cancer Drug Targets 2014; 14 (5) . https://dx.doi.org/10.2174/1568009614666140402105101
DOI https://dx.doi.org/10.2174/1568009614666140402105101 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Snake Venom Peptides and Low Mass Proteins: Molecular Tools and Therapeutic Agents
Current Medicinal Chemistry Current Advances in Food Science & Health Promotion (Part I)
Current Pharmaceutical Biotechnology Cucurmosin Kills Human Pancreatic Cancer SW-1990 Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Subject Index to Volume 4
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial (Thematic Issue: NAD<sup>+</sup> Biosynthesis and Signaling as an Emerging Area in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Medicinal Chemistry Genomic Sequence Analysis of EGFR Regulation by MicroRNAs in Lung Cancer
Current Topics in Medicinal Chemistry Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Construction, Expression and Functional Characterization of the β-Lactamase with αv Integrin Ligands
Protein & Peptide Letters Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development
Current Medicinal Chemistry The Effects of Current Therapies on Airway Remodeling in Asthma and New Possibilities for Treatment and Prevention
Current Molecular Pharmacology Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Preface
Current Drug Targets Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Genetics, Structure, Function, Mode of Actions and Role in Cancer Development of CYP17
Anti-Cancer Agents in Medicinal Chemistry Discharge Interventions and Modifiable Risk Factors for Preventing Hospital Readmissions in Children with Medical Complexity
Reviews on Recent Clinical Trials